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“We shall not cease from exploration
And the end of all our exploring
Will be to arrive where we started
And know the place for the first time.”
Little Gidding by T. S. Eliot (1942)
Introduction
Cardiovascular disease (CVD) is the leading cause of morbidity and
mortality worldwide, responsible for an estimated 17.5 million
deaths in 2005, representing 30% of all deaths (Mudd and Kass,
2008). In Europe alone, CVD causes over 4.3 million deaths each
year, and is the leading cause of death (48%) and disease burden
(23%). Despite substantial advances in medical management, the
prognosis of CVD remains poor, and the identification of
mechanisms and potential therapeutic approaches are still a priority
of considerable importance.
CVD has a very clear environmental component; however, the
risk factors defined in epidemiological studies (e.g. hypertension, high
cholesterol, smoking) explain only a fraction of events (Thanassoulis
and Vasan, 2010). Much hope has been set on the potential of genetics
and genomics to reveal the molecular mechanisms responsible for
the development of CVD and to explain cases that are not obviously
correlated with known risk factors. The strong familial component
of CVD has long been recognized and is evident from the large-scale
population studies that helped to define the classical set of CVD risk
factors. However, studies of CVD heritability are confounded by the
fact that several other risk factors, such as blood pressure, lipid levels
and diabetes, are themselves under genetic control (North et al.,
2003). Nonetheless, several studies have noted that family history is
an independent risk factor (Shea et al., 1984; Myers et al., 1990), so
that CVD heritability does not merely reflect the genetic component
of classical risk factors. Unfortunately, evidence of a high degree of
heritability of a given trait does not mean that identification of the
underlying genes will be straightforward. The analysis of common
multifactorial diseases such as CVD is hindered by the
interdependence of genetic and environmental factors and the
difficulties that are inherent in separating the influence of individual
factors.
In order to fully grasp the contribution of genetics to CVD, we
must go beyond classical Mendelian genetics, and explore the
multiple interacting layers that regulate the genome. This will
include the analysis of not only the protein-coding sequences of
the genome, but the vast non-coding regions as well. An unbiased
view of the whole genome is now possible, thanks to the
development of large-scale approaches led by next generation
sequencing (NGS) technologies. (For a Glossary of terms used, see
Box 1.) In this review, we discuss how studying the many layers
regulating the genome – including chromatin structure, cis-
regulatory elements, microRNAs and alternative splicing – is
beginning to provide us with a fresh view of the development of
and therapeutic strategies for CVD.
The past: understanding the heritability of CVD
To date, most knowledge about genes causing CVD comes from
the study of congenital heart defects and rare forms of familial
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Cardiovascular disease (CVD) is a major cause of mortality and hospitalization worldwide. Several risk factors have been
identified that are strongly associated with the development of CVD. However, these explain only a fraction of cases,
and the focus of research into the causes underlying the unexplained risk has shifted first to genetics and more
recently to genomics. A genetic contribution to CVD has long been recognized; however, with the exception of certain
conditions that show Mendelian inheritance, it has proved more challenging than anticipated to identify the precise
genomic components responsible for the development of CVD. Genome-wide association studies (GWAS) have
provided information about specific genetic variations associated with disease, but these are only now beginning to
reveal the underlying molecular mechanisms. To fully understand the biological implications of these associations, we
need to relate them to the exquisite, multilayered regulation of protein expression, which includes chromatin
remodeling, regulatory elements, microRNAs and alternative splicing. Understanding how the information contained in
the DNA relates to the operation of these regulatory layers will allow us not only to better predict the development of
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inherited CVD. Congenital heart defects can be non-syndromic or
syndromic (such as Holt-Oram and DiGeorge syndromes), and
usually affect genes involved in the early phases of heart
development; these genes can encode transcription factors (such
as Gata4, Nkx2.5 or Tbx factors), signaling pathway components
(such as those of the Notch or the Ras-MAPK pathways) or
structural proteins (such as the -myosin heavy chain encoded by
the MYH6 gene) (Srivastava, 2006). Cardiac developmental defects
are the most common human birth defects (Hoffman and Kaplan,
2002) and their study remains of great importance. Furthermore,
a still-uncharted territory is that of developmental defects that do
not cause an overt fetal phenotype but that subtly impair proper
cardiac function or stress responses and are an underlying
morphological substrate for later-onset CVD.
Familial conditions are usually caused by autosomal dominant
mutations that show a variable degree of expressivity. Identification
of the culprit genes underlying these inherited CVDs has allowed
genetic testing in families with affected members, therefore
allowing counseling and prevention in asymptomatic carriers
(Tester and Ackerman, 2011). Inherited heart diseases are broadly
classified into cardiomyopathies and channelopathies. In
cardiomyopathies, such as hypertrophic cardiomyopathy or
arrhythmogenic right ventricular cardiomyopathy, there is a
structural alteration in the heart (Watkins et al., 2011). By contrast,
the hearts of individuals with channelopathies are structurally
normal, but these conditions, such as long QT or Brugada
syndromes, mainly cause arrhythmias and can result in sudden
cardiac death (Bastiaenen and Behr, 2011).
Although information gained from the study of these and other
conditions has been extraordinarily useful in defining the genetic
basis of cardiovascular morphology and physiology, they only
account for a very small fraction of heritable CVDs. The existence
of these conditions has also prompted numerous studies in which
candidate genes, identified because of their developmental function
in animal models or in tissue culture assays, have been screened
for disease association in affected families or small case-control
studies. However, many associations identified in this way have not
been replicated, showing the inherent limitations of this approach
(Ioannidis et al., 2001; Morgan et al., 2007).
The present: GWAS, eQTLs and exome sequencing
Genome-wide association studies
The sequencing of the human genome, together with an ever
expanding catalog of variations mapped as single nucleotide
polymorphisms (SNPs), has allowed large-scale genome-wide
association studies (GWAS), which have the potential to fill the
gap in our understanding of the genetic basis of CVD and other
common diseases (Hirschhorn and Daly, 2005). Because they
examine the entire genome in an unbiased fashion, GWAS
approaches can identify any genomic region involved in a given
disease and should therefore be free of any kind of ascertainment
bias, which is the main problem with candidate gene approaches.
Overall, there is no doubt that GWAS have provided interesting
new biological insights into many conditions. Surprising findings
include the discovery of SNPs in genes that were originally not
thought to have a role in disease and the identification of loci shared
by diseases, including CVDs, that were previously thought to be
unrelated (Pandey, 2010; O’Donnell and Nabel, 2011).
However, GWAS have, in the view of many, failed to deliver as
expected. The main criticisms are that the identified alleles explain
only a small fraction of the heritability of common diseases and
traits (Manolio et al., 2009) and have a low predictive value
compared with classical risk factors (Thanassoulis and Vasan, 2010).
Possible reasons for this apparent failure are that initial expectations
were too high or that the wrong questions were posed. In addition,
because GWAS are designed to identify common variants, the
existence of rare variants with a large effect has not been addressed.
Consequently, initial hopes that the identification of a small number
of SNPs would explain the inheritance of CVD and other diseases
and serve as predictors, similarly to classical Mendelian inheritance,
have not been realized, because this is not the aim of GWAS.
GWAS methodology has improved and possible explanations for
missing heritability are currently being explored (Zuk et al., 2012);
moreover, ongoing investigation of GWAS results continues to
increase the number of variants associated with common traits. A
major strategy developed to overcome the limitations of GWAS is
a brute-force attack by means of meta-analysis, in which
information from multiple GWAS analyses is pooled to increase
the number of cases and controls analyzed (Cantor et al., 2010;
Pandey, 2010). Another strategy to refine and complement GWAS
is targeted re-sequencing of disease-associated loci to identify rare
or causal variants. This approach has successfully identified rare
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Box 1. Glossary: approaches for studying layers of
genomic regulation
ChIP-seq: combines chromatin immunoprecipitation (ChIP) with next
generation sequencing to identify the binding sites of DNA-associated
proteins. It can be used to map global binding sites precisely for any protein of
interest. Previously, ChIP-on-chip was the most common technique used to
study these protein-DNA relationships.
Chromatin immunoprecipitation (ChIP): a technique used to identify
potential regulatory sequences by isolating soluble DNA chromatin extracts
(complexes of DNA and protein) using antibodies that recognize specific DNA-
binding proteins.
DNAse I hypersensitivity assay: a method for detecting sites throughout the
genome that are more easily cleaved by DNase I owing to an open chromatin
configuration; these sites are usually associated with active regulatory
elements.
Exome sequencing: an efficient strategy to selectively sequence the exome –
the subset of a genome that is protein coding – as a cheaper but still effective
alternative to whole genome sequencing. Exons are short, functionally
important sequences of DNA that represent the regions in genes that are
translated into protein.
Formaldehyde-assisted isolation of regulatory elements (FAIRE): an
approach used to identify regulatory genomic regions based on their open
conformation and their loose association with structural proteins. Sheared
chromatin is subjected to phenol-chloroform extraction; protein-free
chromatin remains in the aqueous solution, whereas tightly packed chromatin
is retained in the organic phase. FAIRE-enriched chromatin can then be
sequenced by next generation DNA sequencing (FAIRE-seq).
Genome-wide association studies (GWAS): studies that search for a
population association between a phenotype and a particular allele by
screening loci (most commonly by genotyping SNPs) across the entire
genome.
Next generation DNA sequencing (NGS): highly parallel DNA sequencing
technology that produces many hundreds of thousands or millions of short
reads (25-500 bp) at low cost and in a short time. Currently, most established
sequencing platforms include the Illumina/Solexa Analyzers, Roche/454
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variants associated with hypertriglyceridemia (Johansen et al.,
2010), although exactly how the rare and common variants interact
and associate with the disease is still unclear.
Despite the limitations of GWAS analyses, their unbiased
searching of the whole genome for associations has identified
previously unknown genetic components of CVD. Some of the
discovered loci were completely unexpected, opening new avenues
of research into the pathways and processes underlying disease.
For example, variants discovered at the 9p21 region were the first
common genetic variants identified as genetic risk factors for
coronary artery disease and other forms of CVDs independent of
classical risk factors (Burton et al., 2007; Helgadottir et al., 2007;
McPherson et al., 2007; Samani et al., 2007). The SNP variants in
the 9p21 gene desert region constitute an early and elegant example
of how disease association can be related to molecular phenomena.
Different mechanisms for this association have been proposed, such
as disruption of regulatory elements involved in the interferon-
signaling response (Harismendy et al., 2011) or of a non-coding
RNA (Pasmant et al., 2011). Another unexpected association is that
of SORT1, encoding the multi-ligand sorting protein sortilin 1, with
plasma low-density-lipoprotein cholesterol levels and myocardial
infarction; this association has uncovered a newly identified
pathway involved in lipid metabolism and CVD, thus offering new
possibilities for therapeutic intervention (Dube et al., 2011).
It is also notable that many disease-associated variants identified
by GWAS are located in loci that have previously been linked to
Mendelian diseases (Lupski et al., 2011). For example, mutations
in KCNE1, encoding a potassium channel subunit, are responsible
for congenital long QT syndrome (Splawski et al., 2000) and Jervell
and Lange-Nielsen syndrome, and GWAS-identified variants near
this gene are associated with QT interval duration (Newton-Cheh
et al., 2009). A similar finding has been reported for SCN5A, which
is associated with Brugada syndrome (Ruan et al., 2009). Therefore,
classical Mendelian genetics and some GWAS converge on a
similar range of genomic loci, the only difference being the nature
and effect of the variants (Lupski et al., 2011).
Gene expression and eQTLs
Gene expression in heart disease has been studied for a long time.
Some genes, such as NPPA [which encodes atrial natriuretic factor
(ANF)], NPPB [brain natriuretic peptide (BNP)], ACTA1 (-skeletal
actin) and MYH7 (-myosin heavy chain), are known to be induced
in stressed cardiomyocytes in infarcted, hypertrophic and dilated
hearts. Indeed, some of these genes have been used for diagnosis
and prognosis in heart disease.
Gene expression in the heart is strongly heritable (Petretto et
al., 2006), which suggests that it is genetically controlled. By
combining microarray studies with genetic linkage analysis we can
identify control points in the genome that regulate gene expression.
These are considered expression quantitative trait loci (eQTL) and
can help reveal genetic associations for certain traits for which
GWAS has not provided a clear answer. One such trait is left
ventricular mass, a risk factor for heart failure and a predictor of
all-cause mortality. By using microarray and linkage analysis, an
association was found, both in rats and humans, between increased
left ventricular mass and elevated expression of the extracellular
matrix protein osteoglycin (Petretto et al., 2008). After hypertrophic
stimulation, osteoglycin knockout mice show reduced ventricular
mass compared with wild-type mice, establishing a causal
relationship between osteoglycin expression and increased left
ventricular mass. The same group recently established an
association between ventricular mass and endonuclease G (Endog),
a mitochondrial nuclease that controls mitochondrial mass
(McDermott-Roe et al., 2011). Loss-of-function mutations in Endog
result in increased left ventricular mass and a decline in cardiac
function in rats. Deletion of the Endog gene in mice induces
mitochondrial depletion and dysfunction, increased oxidative
stress, and cardiac steatosis and hypertrophy. eQTL analysis has
also unveiled an inflammatory network, driven by interferon
regulatory factor 7 (Irf7), that is mainly expressed by monocytes
and macrophages and is associated with susceptibility to type 1
diabetes (Heinig et al., 2010). Expression of the genes in this network
correlates with genetic variation in Epstein-Barr virus-induced gene
2 (Ebi2), suggesting that the network is controlled by this gene.
These studies reveal how eQTL analysis can improve our
knowledge of the biological basis of CVD.
Exome sequencing
With the advent of NGS technologies, exome sequencing – the
targeted sequencing of the portion of the human genome that is
protein coding – has become a widely used tool for discovering
rare alleles underlying Mendelian phenotypes and complex traits.
Although recent examples abound of the successful use of exome
sequencing to identify genes underlying monogenic disorders
(Bamshad et al., 2011), this approach has yet to make a major
contribution to our understanding of complex diseases, and is
currently the focus of a major debate. Large-scale sequencing efforts
have shown that putative loss-of-function variants in protein-
coding genes are abundant in apparently healthy individuals
(MacArthur and Tyler-Smith, 2010; Conrad et al., 2011), which calls
for caution when establishing causal relations between mutations
identified by exome sequencing and disease etiology. In the
cardiovascular field, exome sequencing has identified several
previously unknown candidate causal genes for Mendelian
disorders, including SHROOM3 for heterotaxy (Tariq et al., 2011)
and ANGPTL3 in cases of familial combined hypolipidemia
(Musunuru et al., 2010). In other cases in which exome sequencing
failed to identify the causal variant, complementary approaches
such as copy-number variation analysis did so; for example,
variation in BAG3 causes familial dilated cardiomyopathy (Norton
et al., 2011). Exome sequencing and what the future holds for this
technology have recently been reviewed (Bamshad et al., 2011).
However, it is likely that this approach will soon be superseded by
whole genome sequencing, which has the advantage of being free
of the ascertainment bias inherent to exome sequencing, which
explores just 1% of the genome.
Layers of regulation in CVD
Genomic analysis has so far fallen short of expectations in terms
of establishing the underlying genetic cause of CVD. Although
associations between certain loci and disease have been found, their
biological impact is not immediately obvious because we remain
largely ignorant of the role of genomic elements located outside
coding regions.
Whole individual genomes will be fully sequenced in the near
future, and comparison of these sequences might identify new
dmm.biologists.org436
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associations with CVD. However, it is arguable whether these data
will yield biological information about the molecular mechanisms
that underlie CVD. Even if this information is encoded in the DNA
sequence and can be found, it is by no means certain that we would
be able to understand it. The production of a particular protein in
a cell from the information encoded in DNA is a process that is
exquisitely controlled; intertwined layers of regulation provide both
qualitative and quantitative control of gene expression. To
understand the real contribution of the different elements in the
genome to CVD, it is crucial to carry out a multilayered analysis
of cells and tissues. Such an approach must include the analysis of
chromatin modification and epigenetic regulation, activation of
regulatory elements, gene transcription, alternative splicing and
non-coding RNAs, among other levels of control (Fig. 1). We
therefore need to look beyond the DNA sequence and integrate
different layers of biological information so that we can return to
the starting point, look again at the DNA sequence and, hopefully,
understand for the first time what is written in it (as prefigured in
Eliot’s poem).
Chromatin modifications
DNA is wound around histones to form chromatin, which is in
turn tightly packed to save space. For gene transcription to occur,
chromatin needs to be locally unwound to make the locus accessible
to the transcription machinery. Different modifications along the
chromatin thread determine whether it will be open or remain
closed. These are mainly acetylation and methylation modifications
of histones and DNA, which can be inherited from cell to cell
through mitosis and constitute an epigenetic level of gene
regulation. Epigenetic regulation is particularly sensitive to
environmental changes and is thought to be a major mechanism
by which external stimuli induce an inheritable response (Ordovas
and Smith, 2010). In addition, differences in epigenetic
modifications might explain changes in disease susceptibility in the
absence of DNA sequence variation. Epigenetic changes are not
written in the DNA sequence but can be detected at a global level
through ChIP-seq, which combines immunoprecipitation of
modified histones linked to DNA with NGS. A recent report
describes distinct epigenetic modifications identified in end-stage
heart failure patients (Movassagh et al., 2011).
Epigenetic modifications are carried out by families of histone
acetyl transferases (HATs), histone deacetylases (HDACs), histone
methyl transferases (HMTs) and histone demethylases (HDMs).
These protein families play a major role in heart development and
disease (Ohtani and Dimmeler, 2011). Histone-modifying enzymes
do not bind to DNA but are recruited by transcription factors,
coactivators and repressors that provide the sequence specificity
that these enzymes lack. Histone acetylation occurs on lysine
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Fig. 1. Gene activity is controlled by multiple layers of regulation. For RNA to be transcribed, chromatin needs to be unwound so that genes can be accessed
by the transcription machinery. Chromatin remodeling is controlled by methylation (Me) and acetylation (Ac) marks on histones that determine how open or
closed the chromatin is. Activation of gene transcription is also controlled by enhancer regulatory elements that can sometimes be several kilobases away. Once
transcribed, the immature mRNA (pre-mRNA) undergoes splicing to remove introns. The inclusion or exclusion of an exon is subject to variation (alternative
splicing), which can generate multiple protein isoforms from a single gene. Splicing regulators are often alternatively spliced themselves (represented by curved
arrow). mRNA translation is regulated by a range of non-coding RNAs (ncRNAs), including microRNAs. Some ncRNAs, such as ceRNAs, can regulate the activity of
microRNAs (represented by curved arrow). These multiple layers of regulation interact with each other; for instance, chromatin modification and microRNAs both
modulate alternative splicing, and ncRNAs can also act as transcriptional enhancers to promote transcription. The different regulatory mechanisms respond to
pathological stimuli by changing both the amounts and the isoforms of the multiple proteins that are involved in tissue homeostasis and the development of
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residues and promotes DNA unwinding to facilitate transcription,
whereas deacetylation has the opposite effect. The role of HDACs
in heart disease is diverse and has been thoroughly studied in animal
models (Haberland et al., 2009). HDAC9 and HDAC5 control
cardiac growth, and knockout mice for Hdac9 are more sensitive
to hypertrophic stimuli (Zhang et al., 2002; Chang et al., 2004).
Furthermore, variants in the vicinity of HDAC9 are implicated in
causing increased risk of large vessel ischemic stroke (Bellenguez
et al., 2012). HDAC2 contributes to the development of cardiac
hypertrophy and re-expression of the fetal gene program associated
with cardiac stress (Trivedi et al., 2007). HDAC3 is necessary for
proper heart metabolism. Cardiac-specific deletion of the gene
encoding this protein results in deregulation of PPAR, lipid
accumulation and massive cardiac hypertrophy. HATs also play
roles in heart disease; for example, alterations in the levels of p300
can lead either to developmental cardiac defects or to hypertrophy
and heart failure (Yao et al., 1998; Miyamoto et al., 2006; Wei et
al., 2008). Although these and other studies highlight roles for HATs
and HDACs in heart development and disease, it should be noted
that these enzymes might have targets other than histones and that
their effects might not necessarily be directly linked to chromatin
modification.
Histones can be methylated on different lysine residues and so
can undergo different degrees of methylation, resulting in distinct
effects on transcription regulation (Ohtani and Dimmeler, 2011).
Loss of K4 (Lys4) trimethylation on histone 3 (H3) deregulates
expression of ion channels and cytoskeleton genes and results in
altered contraction (Stein et al., 2011). Like HDACs, HDMs play a
major role in heart development and disease. In the embryo, the
HDM Jarid2 regulates cardiomyocyte proliferation and is necessary
for proper heart development (Lee et al., 2000; Toyoda et al., 2003).
Another HDM, UTX, acts on trimethylated K27 to de-repress
transcription of cardiac genes and switch on cardiac differentiation
(Lee et al., 2012). In the adult heart, expression of JMJD2A is
increased in individuals with hypertrophic cardiomyopathy and
plays a key role in the development of cardiac hypertrophy, as
revealed through gain- and loss-of-function mouse models (Zhang
et al., 2011). The role of HMTs in the heart is less well understood.
A recent report shows that the HMT DotL1 controls dystrophin
transcription and that DotL1 knockout mice develop dilated
cardiomyopathy (Nguyen et al., 2011). For a full review of the role
of these proteins in cardiovascular development, see Chang and
Bruneau (Chang and Bruneau, 2012).
Chromatin is also remodeled by the Brg1/Brm-associated factor
(BAF) complexes in an ATP-dependent manner. The BAF complex
is composed of several proteins, some of which have been reported
to play a major role in the heart. For example, Brg1 expression is
induced in individuals with hypertrophic cardiomyopathy and is
necessary for cardiac hypertrophy development in mice (Hang et al.,
2010). Another BAF-complex component, Baf60c, plays a major role
in cardiac differentiation and heart development (Lickert et al., 2004).
Together, these reports highlight how chromatin-remodeling
regulators control gene expression and susceptibility to CVD.
Cis-regulatory elements
The identification and characterization of the functional sequence
elements that determine when, where and how much a gene is
expressed is a major goal in biology (Birney et al., 2007; Myers et
al., 2011). Acquiring this knowledge will explain a large fraction of
the genetic component of CVD. However, at present this is a
daunting task because we still have not learned to recognize
regulatory elements based on sequence alone (as can be done for
coding regions), and their identification thus far relies on time-
consuming small-throughput functional assays. Furthermore, there
is still no clear estimate of how many functional elements are
present in the genome, although it is expected that a large fraction
of non-coding sequences (the vast majority of the genome) will
contain such elements. The early observation (Dermitzakis et al.,
2002) that sequence conservation of non-coding regions is
comparable to that of coding regions further supports a functional
role for non-coding regions, because they have been conserved
throughout evolution and subjected to positive selection.
A major frustration with GWAS has been that the great majority
of risk-associated SNPs are in the non-coding portion of the
genome, and usually at a great distance from the nearest protein-
coding gene or in different linkage disequilibrium blocks. This
disappointment arises from the common view that coding variants
will have a more profound effect than those in functional elements
present in the non-coding regions (Cooper and Shendure, 2011).
Nevertheless, there is little direct evidence supporting this, and we
are only starting to glimpse the complexity of gene regulation
through non-coding functional elements. Because these vastly
outnumber coding exons, the abundance of non-coding risk
variants identified by GWAS should come as no surprise.
The advent of new technologies such as ChIP-seq that allow
genome-wide screening to identify regions bound by specific
proteins (transcription factors) or that show certain epigenetic
features (DNA methylation, nucleosome-free regions or histone
modifications) has opened new avenues in the search for functional
cis-regulatory elements. Recent work has shown how combinations
of these epigenetic marks distinguish active from inactive chromatin
regions, or proximal regulatory elements (promoters) from distal
elements (Heintzman et al., 2007; Rada-Iglesias et al., 2011). Active
regulatory elements have also been shown to possess an ‘open’
chromatin configuration characterized by depletion of
nucleosomes, which can be identified by DNAse I hypersensitivity
or FAIRE (formaldehyde-assisted identification of regulatory
elements) assays (Song et al., 2011). With these tools in hand, it is
now possible to generate a catalog of candidate regulatory elements
in distinct genomic regions.
Investigators have begun to use such approaches to determine
the regulatory basis of heart development and function, with the
expectation that such knowledge will yield useful insights into the
genetic component of CVD. Analysis of the binding of the co-
activator protein p300 to chromatin has identified thousands of
putative heart enhancers in mice (Blow et al., 2010) and humans
(May et al., 2011). More importantly, functional testing in mouse
transgenic assays has validated the predicted enhancer function of
a large proportion of these predicted elements. Other studies using
a combination of bioinformatic, conservation and functional
validation have also predicted an extensive list of genomic locations
with putative regulatory activity in the heart (Narlikar et al., 2010).
In other cases, the genome-wide binding profiles of cardiac-
specific transcription factors (including Gata4, Nkx2.5, Tbx5, Srf and
Mef2a) have been defined using in vitro mouse tissue culture systems
(He et al., 2011; Schlesinger et al., 2011). These studies showed that
dmm.biologists.org438
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these factors often bind to the same genomic regions, identifying
cis-regulatory modules, in a similar manner to that described in other
systems such as embryonic stem cells (Chambers and Tomlinson,
2009). The integration of these data with maps of histone
modification, DNA methylation, co-activator and nucleosome
exclusion in cardiovascular tissues will provide a comprehensive view
of how the genome is dynamically regulated in health and disease.
Nevertheless, the generation of complete catalogs of cis-
regulatory elements presents some problems. First, functional
validation of predictions based on genome-wide scans will be only
as good as the assays used. At present, robust assays for enhancer
function are available (both for tissue culture and in vivo
transgenesis). However, novel assays to test for silencer, insulator
or other functions need to be developed and applied in a systematic
fashion to classify predicted elements. Second, once these elements
have been found, it is necessary to identify which genes they act
on. Although common sense would predict that the nearest gene
will be the target, this is not necessarily the case. To address this
issue, high-throughput chromatin interaction maps can be built to
show the genomic architecture in a tissue-specific manner (de Wit
and de Laat, 2012). And last but not least, a major problem facing
studies of tissue-specific patterns of gene regulation is the
availability of samples, both from patients and controls. This is
particularly the case for the study of CVD, because biopsies are
rare and in many circumstances the etiology of the diseased tissue
is complex and multifactorial. Attempts have been made to correlate
changes in gene expression and regulation by using another easily
accessible tissue as a proxy (such as blood). However, careful
analysis shows that gene expression patterns are not correlated even
between closely related samples (Powell et al., 2011).
Alternative splicing
After the completion of the human genome project, researchers
were somewhat puzzled, and fairly disappointed, by the low
number of protein-coding genes in the genome. The 21,000 genes
in the genome must suffice to make the ~1 million proteins
estimated to be present in the human proteome. Protein diversity
originates not so much in DNA, but in RNA. As genes are being
transcribed, introns are removed from the immature mRNA and
exons are linked together in a process known as mRNA splicing.
Rather than being a rigid process, splicing allows alternative
combinations of exons that result in the production of different
proteins from a single gene. In fact, alternative splicing (AS) is
considered the main factor underlying protein diversity.
Virtually all genes (94%) with more than one exon undergo AS.
AS events include exon inclusion or exclusion, mutually exclusive
exons, usage of alternative 5 or 3 splice sites and intron retention.
These changes result in alterations in the final mRNA product that
can lead to shifts in the open reading frame, generation of
premature stop codons (nonsense-mediated decay) or changes in
protein domains. Between 50% and 80% of splicing events are
regulated in a tissue-specific manner (Wang and Burge, 2008). A
recent study using exon microarrays showed reduced splicing
efficiency and altered AS of sarcomeric genes in heart-failure
patients (Kong et al., 2010). However, our knowledge about the
involvement of AS in heart pathophysiology is mainly limited to
individual genes whose different isoforms play diverse roles during
heart failure. For example, AS variants of the troponin I gene reduce
contraction efficiency, and AS-generated titin isoforms alter cardiac
stiffness in individuals with dilated cardiomyopathy (Makarenko
et al., 2004; Feng and Jin, 2010). AS of the sodium channel SCN5A,
which mediates cardioprotection by ischemic preconditioning,
generates two non-functional variants during heart failure (Shang
et al., 2007). Similarly, a splicing variant of cell-cycle-regulated
kinase (CCRK), which promotes cardiomyocyte growth and
survival, is downregulated in heart failure (Qiu et al., 2008). We
have also observed that the CnA1 AS variant of the phosphatase
calcineurin improves cardiac function after infarction instead of
inducing maladaptive hypertrophy like other calcineurin isoforms
(Felkin et al., 2011).
AS is regulated by cis-regulatory genomic sequences that are
present in the alternatively spliced exon and its flanking introns,
and by trans-regulatory factors that recognize these sequences. The
role of some of these trans-regulatory factors has been studied in
animal models. Knockout mice for SF2/ASF, a splicing enhancer
of the serine and arginine-rich (SR) protein family, show contraction
defects that lead to dilated cardiomyopathy and death within the
first 8 weeks of life due to postnatal developmental defects (Xu et
al., 2005). Similarly, knockout of the SR protein SC35 leads to dilated
cardiomyopathy 3-5 weeks after birth, although SC35 itself is not
necessary for cardiac development (Ding et al., 2004). Elevated
levels of the CELF trans-regulatory factor CUGBP1 are associated
with myotonic dystrophy, and overexpression of a dominant-
negative CELF protein results in cardiac hypertrophy, fibrosis and
dilated cardiomyopathy (Ladd et al., 2005; Wang et al., 2007).
Interestingly, Rbm20 knockout mice were recently reported to
develop dilated cardiomyopathy due to defects in titin splicing (Guo
et al., 2012). These defects are also detected in humans with RBM20
mutations. Although these reports highlight the general importance
of AS trans-regulatory factors in embryonic and postnatal
development, their role in the response of the heart to pathological
stimuli and their therapeutic potential has barely been explored.
Non-coding RNAs
Much of what was once considered – somewhat presumptuously
– ‘junk’ DNA has turned out to be actively transcribed to produce
RNAs that do not encode protein information [non-coding RNAs
(ncRNAs)] but instead act as regulators of other RNAs. Depending
on their size, origin or function, ncRNAs are classified as
microRNAs, long non-coding RNAs (lncRNAs) and so on.
Although these elements are transcribed from intergenic or intronic
regions of the genome, they might hold the key to understanding
how genetic variation can impact protein expression.
microRNAs are endogenous small non-coding RNAs of ~22
nucleotides that constitute the predominant form of double-
stranded RNA (dsRNA) in mammalian cells. Unlike other
interference RNAs, most microRNAs do not induce mRNA
cleavage, but instead silence protein expression through post-
transcriptional mechanisms, either preventing mRNA translation
or regulating its stability. Rather than an on-off switch, microRNAs
can be viewed as biological rheostats that fine-tune the expression
of a specific protein (Bartel and Chen, 2004; Baek et al., 2008).
MicroRNA-encoding genes are usually found in intergenic, intronic
or polycistronic regions and lack a canonical TATA box and
introns (Rana, 2007). MicroRNAs are transcribed in the nucleus
mainly by type II RNA polymerases and are processed first by
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Drosha and then by Dicer into a mature microRNA (Rana, 2007).
Depending on its degree of complementarity with the microRNA,
the target mRNA will either be prevented from undergoing
translation or will be degraded (Rana, 2007). Target mRNAs often
carry more than one microRNA-recognition sequence in their
3UTR and can sometimes be regulated by two different
microRNAs. In addition, each microRNA can target up to hundreds
of different mRNAs, the efficiency depending on the
complementarity between microRNA and mRNA (Baek et al.,
2008). MicroRNAs play a major role in CVD, which has been
discussed extensively elsewhere (Latronico and Condorelli, 2009).
lncRNAs play diverse – and somewhat unexpected – regulatory
roles (Wilusz et al., 2009). Long intergenic non-coding RNAs
(lincRNAs) are transcribed from enhancer elements and act as
transcriptional enhancers for neighboring genes (De Santa et al., 2010;
Ørom et al., 2010), a role also ascribed to some short ncRNAs called
eRNAs (Kim et al., 2010). The mechanism of action of these ncRNAs
is not entirely clear, although they are speculated to facilitate the
assembly of histone-modifying complexes (Ong and Corces, 2011).
An additional category of lncRNAs was recently described, called
competing endogenous RNAs (ceRNAs) (Franco-Zorrilla et al.,
2007; Tay et al., 2011). ceRNAs mimic mRNA target sequences for
microRNAs, resulting in competition between ceRNA and mRNA
for the microRNA. In this way, ceRNAs act as microRNA ‘sponges’,
regulating the availability of microRNAs and indirectly controlling
the amount of protein that will be translated from the mRNA target.
Although nothing is known about ceRNAs in the heart, the ceRNA
linc-MD1 was recently identified as a regulator of muscle
differentiation by sequestering miR-133 and miR-135, which results
in increased expression of their targets (MAML1 and MEF2C) and
activation of muscle-specific transcription (Cesana et al., 2011). More
than 100 lncRNAs were shown to be differentially expressed in
hypertrophic mouse hearts in a recent RNA-seq analysis (Lee et al.,
2011). However, their general function and specific roles in heart
disease remain unknown.
Intertwined regulation
It is important to note that all of the layers of biological regulation
discussed above also control each other (Fig. 1). For instance, both
chromatin modification and microRNAs modulate AS (Kalsotra
et al., 2010; Luco et al., 2010). This regulation is bidirectional:
splicing activation can promote the recruitment of HMTs, and
changes in AS regulatory sequences result in the repositioning of
epigenetic marks (de Almeida et al., 2011; Kim et al., 2011). Like
protein-coding genes, ncRNAs are epigenetically regulated and
some of them can in turn modulate chromatin modification
(Szulwach et al., 2010). As explained above, ncRNAs can also act
as transcriptional enhancers. Together, these reports clearly indicate
that the expression of a protein in a given cell and during a given
time frame is very delicately regulated. If we are to infer information
from DNA sequences, we need to integrate all available data on
the genome together with correlative studies with other -omics
analyses (such as transcriptomics, metabolomics, exposomics),
which will provide a broader conceptual framework within which
to understand the hereditability of common diseases. The
characterization of the majority of these genomic features will
require functional assays in tissue culture or in vivo that will have
to be carried out in animal models of CVD (e.g. mouse, rat, dog,
pig). Another approach that holds great promise is the generation
of patient-specific induced pluripotent stem (iPS) cells, which can
then be differentiated towards a cardiovascular phenotype. Such
‘disease-in-a-dish’ models have begun to be used for the study of
Mendelian CVD (Carvajal-Vergara et al., 2010; Itzhaki et al., 2011;
Yazawa et al., 2011) and population-scale GWAS analysis in iPS-
cell-derived cardiac cells is not far away.
The future
With sequencing costs dropping rapidly, we will be soon shift from
analysis of exomes to genomes, enabling us to interrogate many
more variants that might be important for controlling gene
transcription, splicing or even translation. Technical challenges
remain, but work to surmount these difficulties is progressing
rapidly. For instance, the limitations inherent in the use of human
samples (e.g. myocardium) are being overcome, at least in part,
through the use of improved animal and cellular models that more
closely resemble human physiology, including pigs and other large
animals, and patient-derived iPS cells. There is no doubt that the
discovery of variants that underlie Mendelian and complex traits
will lead to a much deeper understanding of disease mechanisms,
and these insights should, in turn, facilitate the development of
better diagnostics, prevention strategies and targeted therapeutics.
With the advent of whole-genome sequencing on a population scale,
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Fig. 2. Future trends in predicting the risk of CVD. The need to predict the
risk of CVD is undeniable. The Framingham Heart Study defined a set of risk
factors (represented by blue line) that has been the gold standard since the
1960s. However, these classical risk factors only predict a fraction of CVD.
Although large-scale genetic analyses have identified hundreds of risk-
associated common sequence variants (green line), these have added little or
no additional predictive value to the classical risk score. However, this trend is
set to change in the near future, as additional common variants and novel rare
variants are identified. Furthermore, once we gain a better understanding of
how genes and gene variants interact with each other and with environmental
and behavioral factors, a synergistic effect can be expected, and thus our
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the next challenge will be to identify rare variants with possibly
larger effects. For this we will need to interpret non-coding
variation in a similar way to how we predict the effect of coding
variants on the protein product of genes. At present, this is not
possible, but as our understanding of the regulatory genome grows,
we believe this capability will be a reality in the near future. So far,
the predictive value of identified variants associated with CVD is
poor, and barely improves current scores based on classical risk
factors (Thanassoulis et al., 2012). However, novel advances in the
field, together with a better understanding of gene-environment
interactions, will surely result in an increased predictive score for
CVD risk (Fig. 2), and therefore a brighter outlook for early
prevention and diagnosis.
The question that still lingers is how much of our susceptibility
to developing CVD is written in the genome. According to a
deterministic view, the probability of developing CVD and our
susceptibility to environmental factors would be fully coded in the
genome, and consequently our ability to prevent disease would be
conditioned by the depth of our knowledge of this code. The reality
is that we do not know to what extent information contained within
the DNA code predicts disease, and our efforts to discover more
have so far been somewhat naive. On the bright side, identifying
the full predictive potential of the genome is a finite task and as
such can be expected to be completed eventually, even if it takes
decades or centuries. A combination of full genome sequencing,
more powerful questionnaires to identify additional environmental
risk factors, new animal models to study cause-effect relationships
and increased knowledge of regulatory layers will provide the
information needed to establish new correlations with DNA
sequence. Researchers will use these blocks to build regulatory
codes that will better explain the biological role of each piece of
the genome so that we can use genetic variation to predict and
treat disease. With the development of faster computers and
increased bioinformatic expertise, we will one day be in a position
to answer the question of how much information our genome really
contains. Until then, we will have to take things one step at a time.
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